

b) — contacting ~~said an isolated~~ antibody with a sample containing PG1 polypeptides ~~said polypeptide~~ under conditions which allow said antibody to bind said polypeptides,

wherein said PG1 polypeptides comprises at least 8 amino acids of SEQ ID NOs: 4, 5 or 70, and

wherein said antibody specifically binds to a contiguous span of at least 8 amino acids of SEQ ID NOs: 4, 5 or 70.

51. (AMENDED) The method according to claim 50, wherein said method is used to quantitate said polypeptides by ELISA.

52. (AMENDED) The method according to claim 50, wherein said method is used to quantitate said polypeptides by RIA.

53. (ORIGINAL) The method according to claim 50, wherein said contacting occurs on an affinity column.

54. (AMENDED) The method according to claim 50, wherein said ~~polypeptide sample~~ is in a biological sample.

55. (AMENDED) The method according to claim 50, wherein said isolated antibody is monoclonal.

56. (AMENDED) The method according to claim 50, wherein said isolated antibody is polyclonal.

57. (AMENDED) The method according to claim 50, wherein said isolated antibody comprises at least one binding domain.

58. (ORIGINAL) The method according to claim 57, wherein said binding domain is Fab.
59. (ORIGINAL) The method according to claim 57, wherein said binding domain is Fab'.
60. (ORIGINAL) The method according to claim 57, wherein said binding domain is F(ab)₂.
61. (ORIGINAL) The method according to claim 57, wherein said binding domain is F(ab')₂.
62. (NEW) The method according to claim 50, wherein said polypeptides are detected by Western blot.
63. (NEW) The method according to claim 50, wherein said method is used to quantitate isoforms of said polypeptides by ELISA.
64. (NEW) The method according to claim 50, wherein said method is used to quantitate isoforms of said polypeptides by RIA.
65. (NEW) The method according to claim 50, wherein isoforms of said polypeptides are detected by Western blot.